{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:13:14Z","timestamp":1767816794970,"version":"3.49.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    A 60-year-old man with metastatic castration-resistant prostate cancer (mCRPC), previously treated with antiandrogen therapy, experienced continued PSA rise and disease progression. He subsequently received 2 cycles of low-dose\n                    <jats:sup>161<\/jats:sup>\n                    Tb-PSMA radioligand therapy (RLT) with doses of 0.96 and 1.11\u00a0GBq, respectively. The follow-up results showed that the PSA of the patient decreased, the uptake of the lesions on\n                    <jats:sup>68<\/jats:sup>\n                    Ga-PSMA PET\/CT reduced, and the symptoms of urinary retention were relieved. No acute toxicity or adverse reactions were observed.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006241","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T17:00:14Z","timestamp":1765299614000},"page":"166-167","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The Effectiveness of Low-dose 161Tb-PSMA Treatment for Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"given":"Fucen","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China"},{"name":"NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, Mianyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, Mianyang, China"},{"name":"Institute of Nuclear Physics and Chemistry, Chinese Academy of Engineering Physics, Mianyang, China"},{"name":"Targeted Radiopharmaceuticals Creation Key Laboratory of Sichuan Province, Mianyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China"},{"name":"NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, Mianyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9931-850X","authenticated-orcid":false,"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengguo","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China"},{"name":"NHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, Mianyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s13139-024-00871-4","article-title":"Dual radionuclide therapy: the synergistic effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in advanced prostate cancer post [177Lu]Lu-PSMA failure","volume":"58","author":"Abdlkadir","year":"2024","journal-title":"Nucl Med Mol Imaging"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2967\/jnumed.119.236414","article-title":"Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase ii prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J Nucl Med"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from (161)Tb and (177)Lu in single tumour cells and micrometastases","volume":"7","author":"Alcocer-\u00c1vila","year":"2020","journal-title":"EJNMMI Phys"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00259-013-2563-z","article-title":"Direct in vitro and in vivo comparison of (161)Tb and (177)Lu using a tumour-targeting folate conjugate","volume":"41","author":"M\u00fcller","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2967\/jnumed.122.265291","article-title":"(161)Tb-PSMA radioligand therapy: first-in-humans SPECT\/CT imaging","volume":"64","author":"Al-Ibraheem","year":"2023","journal-title":"J Nucl Med"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2967\/jnumed.124.267650","article-title":"Clinical trial protocol for VIOLET: a single-center, phase I\/II trial evaluation of radioligand treatment in patients with metastatic castration-resistant prostate cancer with [(161)Tb]Tb-PSMA-I&T","volume":"65","author":"Buteau","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T19:00:19Z","timestamp":1767812419000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006241","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"2025-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}